Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
Company Growth (employees)
Milton, GB
Size (employees)
232 (est)+2%
Immunocore is headquartered in Milton, GB

Key People at Immunocore

Eliot Forster

Eliot Forster

Christina Coughlin

Christina Coughlin

Chief Medical Officer
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Eva-Lotta Allan

Eva-Lotta Allan

Chief Business Officer
Namir Hassan

Namir Hassan

Director of Translational Research & Development
Henrik Sorensen

Henrik Sorensen

Head of Alliance Management

Immunocore Office Locations

Immunocore has an office in Milton
Milton, GB (HQ)
101 Park Drive, Milton Park, Abingdon, Oxon

Immunocore Data and Metrics

Summary Metrics

Total Funding

$320 m

Latest funding size

$320 m

Time since last funding

almost 2 years


Immunocore's latest funding round in July 2015 was reported to be $320 m. In total, Immunocore has raised $320 m

Immunocore Financial Metrics

Immunocore's revenue was reported to be £6.4 m in FY, 2014 which is a 212% increase from the previous period.
Numbers are in £, GBP

Revenue (FY, 2014)

6.4 m

Revenue growth (FY, 2013 - FY, 2014), %


Net income (FY, 2014)

(5.6 m)

Cash (30-Sep-2014)

50.9 m
Numbers are in £, GBPFY, 2013FY, 2014


2 m6.4 m

Revenue growth, %


Pre tax profit

(4.8 m)(7.2 m)

Net Income

(3.7 m)(5.6 m)
Numbers are in £, GBPFY, 2013FY, 2014


16.3 m50.9 m

Accounts Receivable

307.3 k203 k

Current Assets

18 m54.3 m


1.3 m6.4 m


257.9 k207 k

Total Assets

19.6 m60.9 m

Accounts Payable

566.6 k825 k

Current Liabilities

8.4 m18.6 m

Retained Earnings

(3.7 m)(5.6 m)

Total Equity

3 m(2.1 m)

Financial Leverage

6.5 x-28.9 x
Numbers are in £, GBPFY, 2013FY, 2014

Cash From Operating Activities

11.3 m40.3 m

Cash From Financing Activities

3 m404 k

Income Taxes Paid

1.1 m1.6 m
Y, 2014

Financial Leverage

-28.9 x

Immunocore Online and Social Media Presence

Immunocore Company Life and Culture

You may also be interested in